CNS drug discovery with translatable neuroscience technology
High attrition rates in CNS clinical trials is an indication that current testing is failing to predict safety/efficacy of compounds. NeuCyte supports early phases of drug discovery programs as well as the investigation of MOAs for experimental compounds. Based on the SynFire® technology, our human neural in vitro platforms are uniquely suited for assessing relevant higher order electrophysiology readouts, which allow for a better predictor of drug efficacy and potential CNS safety/toxicology.